Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases PDF Print E-mail
Thursday, 22 December 2011 20:32
Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. Girgis

Objective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulmonary arterial hypertension [PAH]) or associated with interstitial lung disease (ILD). This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH-specific therapy.

Methods. Consecutive SSc patients with PAH or ILD-associated PH confirmed by right heart catheterization were included in the study. Kaplan-Meier and Cox proportional hazards models were used to compare survival between SSc patients with PAH and those with ILD-associated PH and to identify predictors of survival.

Results. Fifty-nine patients (39 with PAH and 20 with ILD-associated PH) were identified. The majority (15 of 20 with ILD-associated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy. Median followup time was 4.4 years (range 2.7–7.4 years). Survival was significantly worse in SSc patients with ILD-associated PH than in those with PAH (1-, 2-, and 3-year survival rates 82%, 46%, and 39% versus 87%, 79%, and 64%, respectively; P <0.01 by log rank test). In a multivariable analysis, ILD-associated PH was associated with a 5-fold increase in risk of death compared with PAH. Pulmonary vascular resistance index was also an independent predictor of mortality in the overall cohort (hazard ratio 1.05, P <0.01) and was a significant univariable risk factor in
each group separately. Type of initial PAH therapy and the use of warfarin were not related to survival.

Conclusion. Survival in SSc complicated by PH remains poor despite currently available treatment options. While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD-associated PH is particularly grim. Early diagnosis and treatment may improve outcomes since worsening hemodynamic factors were associated with reduced survival.

 
More articles :

» What Is Scleroderma?

DefinitionDerived from the Greek words “sklerosis,” meaning hardness, and “derma,” meaning skin, Scleroderma literally means hard skin. Although it is often referred to as if it were a single disease, Scleroderma is really a symptom of a...

» Treatment for Pulmonary Arterial Hypertension Cleared

has recently reported in its that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to...

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» Clinical Manifestations of Heart Disease In Autoimmune Disorders

Dr. Lawrence Phillips is the Assistant Professor of Medicine, Division of Cardiology and Director of Nuclear Cardiology at the . At the recently concluded , Dr. Phillips presented on the clinical manifestations of heart diseases in autoimmune...

» Digital Ulcers Linked to More Severe Systemic Sclerosis

Digital ulcers are associated with more severe systemic sclerosis (SSc) disease, including skin and lung involvement, but not with pulmonary arterial hypertension (PAH) or scleroderma renal crisis (SRC), according to research published in the...

» Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies

Jessica Gordon and Robert SpieraReceived 1 June 2011; Revised 2 August 2011; Accepted 2 August 2011Systemic sclerosis (SSc) is a heterogeneous, multisystem disorder characterized by vasculopathy, fibrosis, and autoimmunity in the context of both...